Cargando…
38. Remdesivir Treatment in Patients Hospitalized with COVID-19: A Comparative Analysis of In-Hospital All-Cause Mortality
BACKGROUND: Remdesivir (RDV) reduced time to recovery and mortality in some subgroups of hospitalized patients in the NIAID ACTT-1 RCT compared to placebo. Comparative effectiveness data in clinical practice are limited. METHODS: Using the Premier Healthcare Database, we compared survival for adult...
Autores principales: | Mozaffari, Essy, Chandak, Aastha, Zhang, Zhiji, Liang, Shuting, Thrun, Mark, Gottlieb, Robert L, Kuritzkes, Daniel R, Sax, Paul, Wohl, David, Casciano, Roman, Hodgkins, Paul, Haubrich, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644802/ http://dx.doi.org/10.1093/ofid/ofab466.038 |
Ejemplares similares
-
Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort
por: Mozaffari, Essy, et al.
Publicado: (2021) -
Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States
por: Mozaffari, Essy, et al.
Publicado: (2021) -
POSB12 Association Between Remdesivir Treatment and In-Hospital All-Cause Mortality Among Patients Hospitalized with COVID-19
por: Mozaffari, E, et al.
Publicado: (2022) -
Comparative effectiveness research in COVID-19 using real-world data: methodological considerations
por: Read, Stephanie H, et al.
Publicado: (2021) -
PIN82 Real-World Utilization of Remdesivir in 2020: A Retrospective Cohort Study
por: Mozaffari, E., et al.
Publicado: (2021)